Utility of ASNS gene methylation evaluated with the HPLC method as a pharmacogenomic biomarker to predict asparaginase sensitivity in BCP-ALL

References

• Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(28):7161–9. doi: 10.1200/JCO.2005.11.411
   PubMed Web of Science ®Google Scholar
• Sallan SE, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983;43(11):5601–5607.
   PubMed Web of Science ®Google Scholar
• Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986;315(11):657–663. doi: 10.1056/NEJM198609113151101
   PubMed Web of Science ®Google Scholar
• Kaspers GJ, Smets LA, Pieters R, et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood. 1995;85(3):751–756. doi: 10.1182/blood.V85.3.751.bloodjournal853751
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211–1218. doi: 10.1182/blood.V97.5.1211
   PubMed Web of Science ®Google Scholar
• Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European organisation for research and treatment of cancer-children’s leukemia group phase 3 trial. Blood. 2002;99(8):2734–2739. doi: 10.1182/blood.V99.8.2734
   PubMed Web of Science ®Google Scholar
• Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109(3):896–904. doi: 10.1182/blood-2006-06-027714
   PubMed Web of Science ®Google Scholar
• Children’s Cancer Group Study CCG-1961, Panosyan EH, Seibel NL, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children’s Cancer Group study CCG-1961. J Pediatr Hematol Oncol. 2004;26(4):217–226.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study - Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013;31(9):1202–1210. doi: 10.1200/JCO.2012.43.2070
   PubMed Web of Science ®Google Scholar
• Kawedia JD, Liu C, Pei D, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood. 2012;119(7):1658–1664. doi: 10.1182/blood-2011-09-381731
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Attarbaschi A, Barzilai S, et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016 Jun;17(6):e231–9. doi: 10.1016/S1470-2045(16)30035-3
   PubMed Web of Science ®Google Scholar
• Hijiya N, van der Sluis IM. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2016;57(4):748–757. doi: 10.3109/10428194.2015.1101098
   PubMed Web of Science ®Google Scholar
• Pieters R, Huismans DR, Loonen AH, et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet. 1991;338(8764):399–403. doi: 10.1016/0140-6736(91)91029-T
   PubMed Web of Science ®Google Scholar
• Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 1997;90(7):2723–2729. doi: 10.1182/blood.V90.7.2723
   PubMed Web of Science ®Google Scholar
• Fischer U, Forster M, Rinaldi A, et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet. 2015 Sep;47(9):1020–1029. doi: 10.1038/ng.3362
   PubMed Web of Science ®Google Scholar
• Iwamoto S, Mihara K, Downing JR, et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest. 2007;117(4):1049–1057. doi: 10.1172/JCI30235
   PubMed Web of Science ®Google Scholar
• Watanabe A, Miyake K, Nordlund J, et al. Association of aberrant ASNS imprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALL. Blood. 2020;136(20):2319–2333. doi: 10.1182/blood.2019004090
   PubMed Web of Science ®Google Scholar
• Akahane K, Kimura S, Miyake K, et al. Association of allele-specific methylation of the ASNS gene with asparaginase sensitivity and prognosis in T-ALL. Blood Adv. 2022;6(1):212–224. doi: 10.1182/bloodadvances.2021004271
   PubMed Web of Science ®Google Scholar
• Yotani T, Yamada Y, Arai E, et al. Novel method for DNA methylation analysis using high-performance liquid chromatography and its clinical application. Cancer Sci. 2018;109(5):1690–1700. doi: 10.1111/cas.13566
   PubMed Web of Science ®Google Scholar
• Zilberman D, Henikoff S. Genome-wide analysis of DNA methylation patterns. Development. 2007;134(22):3959–3965. doi: 10.1242/dev.001131
   PubMed Web of Science ®Google Scholar
• Illumina, inc. Planning your NGS budget. [cited 2021 Dec 14]. Available from: https://www.illumina.com/science/technology/next-generation-sequencing/beginners/ngs-cost.html.
   Google Scholar
• van der Hagen EAE, Leppink S, Bokkers K, et al. Evaluation of the ARKRAY HA-8190V instrument for HbA1c. Clin Chem Lab Med. 2021;59(5):965–970. doi: 10.1515/cclm-2020-1300
   PubMed Web of Science ®Google Scholar
• Nikolin B, Imamović B, Medanhodzić-Vuk S, et al. High performance liquid chromatography in pharmaceutical analyses. Bosn J Basic Med Sci. 2004 May;4(2):5–9. doi: 10.17305/bjbms.2004.3405
   PubMedGoogle Scholar
• Hanihara M, Miyake K, Watanabe A, et al. Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma. Clin Epigenet. 2020;12(1):174. doi: 10.1186/s13148-020-00968-5
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003. doi: 10.1056/NEJMoa043331
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085–4091. doi: 10.1200/JCO.2013.49.6968
   PubMed Web of Science ®Google Scholar
• Moorman AV, Robinson H, Schwab C, et al. Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials. J Clin Oncol. 2013;31(27):3389–3396. doi: 10.1200/JCO.2013.48.9377
   PubMed Web of Science ®Google Scholar
• Touzart A, Lengliné E, Latiri M, et al. Epigenetic silencing affects l-asparaginase sensitivity and predicts outcome in T-ALL. Clin Cancer Res. 2019;25(8):2483–2493. doi: 10.1158/1078-0432.CCR-18-1844
   PubMed Web of Science ®Google Scholar